Abstract
Interstitial lung disease (ILD) is a life-threatening complication of systemic sclerosis (SSc). Type 2 (Th2) cytokines play a pivotal role in airway disease. Study aim was to evaluate serum level of Th2 interleukin (IL) and chemokine in SSc-ILD. Serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31 and CXCL-13 were measured by Bio-Plex Multiplex Immunoassays in 60 SSc patients and 20 healthy controls (HC). Pulmonary function tests with diffusion lung capacity for carbon monoxide (DLco) and high resolution computed tomography (HRCT) were performed in SSc patients. ILD is defined as fibrotic changes (ground glass, reticular and honeycombing), assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software, affecting at least 10% of the lungs. Serum levels of Th2 cytokines were higher in SSc patients than HC. A linear correlation was observed between ground glass and IL-13 (r = 0.342, p < 0.01), IL-21 (r = 0.345, p < 0.01), IL-31 (r = 0.473, p < 0.001), IL-4 (r = 0.863, p < 0.001), IL-5 (r = 0.249, p < 0.05) and peripheral blood eosinophils (r = 0.463, p < 0.001). We found a negative correlation between DLco and IL-4 (r = − 0.511, p < 0.001) and peripheral blood eosinophils (r = − 0.446, p < 0.001). In the logistic regression analysis, IL-4 is associated with DLco ≤ 60% of the predicted [OR 1.039 (CI 95%: 1.015–1.064), p < 0.001], whilst mRSS [OR 1.138 (CI 95%: 1.023–1.266), p < 0.05] and IL-4 [OR 1.017 (CI 95%: 1–1.034), p < 0.05] were associated with ILD. Th2 inflammation could play a key role in early phase of SSc-ILD.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by immune system dysregulation, endothelial dysfunction and fibrosis of skin and internal organs. Interstitial lung disease (ILD) is common in SSc and about 80% of patients will develop ILD during the disease course [1]. Although most patients have a stable or slowly progressive disease, showing a slow decline in lung function or a minimal increase in the extent of pulmonary fibrosis by high resolution computed tomography (HRCT), 25–30% of them will ultimately progress to respiratory failure or death [2]. Of the SSc-related deaths, 35% were attributed to ILD [3].
The underlying pathophysiologic mechanisms of SSc-ILD is still not completely understood [2]. The pathogenesis of SSc-ILD is initially characterized by an injury to alveolar epithelial and vascular endothelial cells which promotes the activation of the immune system and the recruitment of inflammatory cells and the production of profibrotic mediators, in the attempt to repair the damage, with accumulation of myofibroblasts [4, 5]. Infiltration by inflammatory T cells is thought to precede the development of lung fibrosis and in this early inflammatory phase, profibrotic type 2 (Th2) cytokines, such as IL-4, IL-5, IL-13, play a key role [6, 7]. Indeed, an abnormal profibrotic Th2-polarized T cell response has been postulated to mediate tissue damage and fibrosis in SSc-ILD as Th2 cytokines lead to the activation of alternative inflammatory pathways and to the transcription of transforming growth factor (TGF)-β, involved in induction and progression of fibrosis [8, 9]. Moreover, it has been demonstrated that IL-4/IL-13 axis upregulate genes known to be involved in the mechanisms of wound healing and fibrosis in murine models and in vitro, influencing the activation of myofibroblasts [10].
Th2 cytokines also contribute to the differentiation and migration of eosinophils, which are involved in systemic inflammatory process in SSc patients [11,12,13]. In the earlier course of ILD, pulmonary function tests (PFTs) show a reduction of the diffusion lung capacity for carbon monoxide (DLco) with preserved forced vital capacity (FVC) and HRCT shows a ground glass pattern with typical subpleural and posterobasal distribution [14]. At a later stage, fibroblasts proliferation and activation lead to extracellular matrix deposition and fibrosis of the lung parenchyma. PFTs show a restrictive pattern with a further decline of DLco and a reduction of FVC [14]. HRCT shows a reticular pattern with intralobular opacity and thickening of the interlobular septa and, eventually, a honeycombing pattern with traction bronchiectasis [14]. Aim of the study was to evaluate the Th2 cytokines serum levels in SSc-ILD.
Materials and methods
Subjects
Sixty SSc patients, fulfilling the American College of Rheumatology/European League Against Rheumatism Collaborative Criteria (2013 ACR/EULAR) for SSc [15] and twenty healthy controls (HC), matched for sex and age and recruited among healthcare workers, were enrolled in this study.
Cardiopulmonary diseases not related to SSc, pulmonary arterial hypertension (PAH), heart and hepatic failure, end stage renal diseases, malignancies, allergic diseases were exclusion criteria. Smokers, pregnant or breastfeeding women and patients treated in the last 6 months with immunosuppressive agents and corticosteroids at an equivalent dose of prednisone ≥ 10 mg/day were also excluded.
The study was conducted according to the Declaration of Helsinki and all participants provided written informed consent. The study was approved by the ethics committee of Sapienza University (IRB 0304).
Clinical assessment
The modified Rodnan skin score (mRSS) was used to assess skin involvement and the disease subset was assessed according to LeRoy et al. [16] Disease activity and disease severity were measured by the disease activity index (DAI) [17] and disease severity scale (DSS) [18], respectively.
Nailfold videocapillaroscopy
Nailfold videocapillaroscopy (NVC) was performed at the level of the distal phalanx of the second, third and fourth fingers of both hands using a videocapillaroscope equipped with a 500 × magnification lens (Pinnacle Studio Version 8 software, Corel, Ottawa, Canada). According to Cutolo et al. [19], the capillaroscopic images were classified in early, active, and late pattern. The NVC was performed by the same experienced operator, blinded for laboratory assessment and for other clinical characteristics of SSc patients.
Pulmonary function tests
PFTs parameters [forced expiratory volume in the 1st second (FEV1), FVC] and single-breath DLco were recorded by the same blinded experienced operator with a Quark PFT 2 spirometer (Cosmed, Rome, Italy) and expressed according to the standards recommended by the American/European Respiratory Society [20]. PFTs were performed at enrollment in this study.
Chest high-resolution computed tomography
The HRCT performed during the study or in the previous 6 months were evaluated by the same expert radiologist. ILD was defined as fibrotic changes affecting at least 10% of the lung parenchyma according to previous study [21]. Radiological patterns (normal, ground glass, reticular, and honeycombing) were measured and expressed as percentage of total lung parenchyma through Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software by the same blinded radiologist [22].
Laboratory assessment
Peripheral venous blood samples were collected in tubes and centrifuged at 3000 × g for 15 min at 19 °C. Serum samples were aliquoted into 1.5 mL Eppendorf tubes and stored at − 80 °C until the time of assay. The assessment of serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31, CXCL-13 cytokines was carried out using a Bio-Plex Multiplex Immunoassays allow to simultaneously measure analytes available as ready-to-use premixed multiplex panels (BIO-RAD, Hercules, CA, USA). All blood tests were performed in a single analytical session, following the instructions provided by the manufacturers. Each sample was tested twice to minimize eventual discrepancies, and all tests were performed in the same laboratory with the same instrument by the same experienced operator, blinded of the clinical information of the handled sample.
Statystical analysis
SPSS version 26.0 software (Bioz, Los Altos, CA) was used for statistical analysis. After an evaluation of normality by using the Shapiro–Wilk test, continuous variables were expressed as median and interquartile range (IQR). Student’s or Mann–Whitney’s t-test were performed to evaluate differences between groups. Differences between categorical variables were evaluated by the chi-square or Fisher’s exact test, as appropriate. The Pearson or Spearman correlation test was used for bivariate correlations. Stepwise logistic regression analysis was used to evaluate the association between a dependent dichotomic variable (ILD or DLco ≤ 60% of the predicted) and continuous [age (years), duration disease (years), mRSS, IL-4 (pg/ml)] or cathergorical [Scl70 (yes or no)] independent variables. Results were expressed as odds ratio (OR) and 95% confidence interval (95% CI). A p-value < 0.05 was considered significant.
Results
Fifty-five (91.7%) patients were females. Median age was 56 years (IQR 49–63 years). Thirty-one (51.7%) patients had diffuse cutaneous SSc (dcSSc) and 29 (48.3%) had limited cutaneous SSc (lcSSc). Thirteen (21.7%) patients had DLco ≤ 60% of predicted and 19 (31.7%) patients had radiological ILD. Demographic and clinical features of SSc patients are shown in Table 1.
The median value of circulating eosinophils was 135/μl (IQR 65–195). Only 3 (5%) patients had peripheral blood eosinophils ≥ 300/μl whilst 29 (46.8%) patients had peripheral blood eosinophils ≥ 150/μl. The median value of serum IgE was 85 KU/l (IQR 61.50–99.5).
SSc patients had a statistically significant higher median value of Th2 cytokines and chemokine than HC (Table 2). Median CXCL-13 serum levels were significantly higher in SSc patients compared to HC [124.97 ng/ml (IQR 82.78–212.92) vs 76.55 ng/ml (IQR 48.58–105.18), p < 0.001]. Median IL-11 serum levels were significantly higher in SSc patients compared to HC [239.16 ng/ml (IQR 172.46–351.81) vs 33.14 ng/ml (IQR 26.49–98.25), p < 0.001]. Median IL-13 serum levels were significantly higher in SSc patients compared to HC [241.47 ng/ml (IQR 164.35–460.7) vs 68.54 ng/ml (IQR 48–103.6), p < 0.001]. Median IL-21 serum levels were significantly higher in SSc patients compared to HC [130.25 ng/ml (IQR 57.05–259.78) vs 17.52 ng/ml (IQR 14.83–27.13), p < 0.001]. Median IL-31 serum levels were significantly higher in SSc patients compared to HC [298.12 ng/ml (IQR 180.81–398.6) vs 55.71 ng/ml (IQR 41.98–83.06), p < 0.001]. Median IL-4 serum levels were significantly higher in SSc patients compared to HC [111.06 ng/ml (IQR 92.09–136.64) vs 16.68 ng/ml (IQR 11.68–29.37), p < 0.001]. Median IL-5 serum levels were significantly higher in SSc patients compared to HC [15.73 ng/ml (IQR 11.65–19.24) vs 5.93 ng/ml (IQR 4.46–6.61), p < 0.001].
We found a statistically significant positive correlation between ground glass CALIPER pattern and IL-4 (r = 0.863, p < 0.001) and IL-31 (r = 0.473, p < 0.001) (Fig. 1a–b). Moreover, we showed a slightly statistically significant positive correlation between ground glass CALIPER pattern and IL-21 (r = 0.345, p < 0.01), IL-13 (r = 0.342, p < 0.01) and IL-5 (r = 0.249, p < 0.05) (Fig. 1c–e). A statistically significant negative correlation exists between normal CALIPER pattern and IL-4 (r = − 0.414, p < 0.001). In addition, we found a slightly statistically significant negative correlation between normal CALIPER pattern and IL-31 (r = − 0.289, p < 0.05) and IL-13 (r = − 0.224, p < 0.05). Finally, we showed a statistically significant negative correlation between IL-4 and honeycombing CALIPER pattern (r = − 0.281, p < 0.05) (Fig. 1f). We found a statistically significant negative correlation between IL-4 and DLco (r = − 0.511, p < 0.001) (Fig. 2a). Moreover, we showed a slightly statistically significant negative correlation between DLco and IL-5 (r = − 0.259, p < 0.05) and IL-31 (r = − 0.258, p < 0.05) (Fig. 2b–c). No statistically significant correlations exist between CXCL-13 or IL-11 and DLco or CALIPER pattern.
A statistically significant positive linear correlation was found between peripheral blood eosinophil count and IL-4 (r = 0.598, p < 0.001), IL-5 (r = 0.559, p < 0.001), IL-13 (r = 0.366, p < 0.01), IL-21 (r = 0.469, p < 0.001), IL-11 (r = 0.274, p < 0.05), IL-31 (r = 0.345, p < 0.01) and CXCL-13 (r = 0.309, p < 0.01). Moreover, we found a statistically significant positive correlation between peripheral blood eosinophil count and ground glass CALIPER pattern (r = 0.463, p < 0.001) (Fig. 3a) and a statistically significant negative correlation between peripheral blood eosinophil count and DLco (r = − 0.446, p < 0.001) (Fig. 3b). The percentage of ground glass parenchyma was higher in SSc patients with peripheral blood eosinophils ≥ 150/μl compared to SSc patients with peripheral blood eosinophils < 150/μl [2.89% (IQR 2.10–5.40) vs 1.5% (IQR 0.76–4.90), p < 0.05] (Fig. 3c).
We did not find any statistically significant correlation between serum IgE and DLco (r = 0.144, p > 0.05) or ground glass CALIPER pattern (r = − 0.03, p > 0.05).
The logistic regression analysis showed IL-4 as the only variable associated with DLco ≤ 60% of the predicted [OR 1.039 (CI 95%: 1.015–1.064), p < 0.001] (Table 3). The logistic regression analysis showed mRSS [OR 1.138 (CI 95%: 1.023–1.266), p < 0.05] and IL-4 [OR 1.017 (CI 95%: 1–1.034), p < 0.05] as variables associated with ILD (fibrotic involvement ≥ 10% of lung parenchyma) in SSc patients (Table 3).
Discussion
In this study, we demonstrated increased Th2 cytokines serum levels in SSc patients compared to HC. Moreover, we found a positive linear correlation between serum Th2 cytokines and the extent of ground glass pattern assessed by CALIPER software in SSc patients. Finally, IL-4 was associated with DLco ≤ 60% of the predicted and with fibrotic involvement of ≥ 10% of lung parenchyma in SSc patients.
In our study, we demonstrated that serum level of Th2 interleukin and chemokine are increased in SSc patients than HC. In SSc pathogenesis, the role of Th2 inflammation is misunderstood. The role of inflammation, especially Th2 inflammation, in the SSc ILD has long been debated [23, 24]. Th2 cytokines, released in early ILD inflammatory phase, lead to the activation of alternative inflammatory pathways and to the transcription of TGF-β, involved in induction and progression of fibrosis [9]. According to previous studies [11, 25], we demonstrated increased Th2 cytokines serum levels in SSc patients compared to HC. Moreover, and more importantly, we found a positive linear correlation between the percentage of ground glass on HRCT and Th2 cytokines serum levels (IL-4, IL-31, IL-21, IL-13 and IL-5) in SSc patients. IL-21 seems to stimulate a Th2 dependent fibrotic response by acting as a trigger on IL-4 and IL-13, indeed it has been shown that there is an association between IL-4 and IL-21/IL-21R mRNAs, suggesting that IL-21 can promote fibrosis by facilitating the development of a Th2 response [26]. It is well known that IL-4/IL-13 axis upregulate genes known to be involved in the mechanisms of wound healing and fibrosis in murine models and in vitro [10]. IL-13 is required for an effective Th2 immune response and appears to have a direct profibrotic function [24]. IL-13 promotes epithelial metaplasia and remodeling of the airways by acting on the same receptor as IL-4, acting directly on the production of TGF-β or stimulating its signaling mediated by Smad [10]. Several studies suggested that Th2 cytokines contributed to the SSc pathogenesis and it is well known that some of these cytokines play a key role in the differentiation and migration of eosinophils, which are involved in inflammatory process in SSc patients [13]. IL-4 and IL-13 promote the secretion of IL-5 to activate eosinophils inducing fibroblast proliferation and promoting the expression of TGF-β and the epithelial-mesenchymal transition [27]. There is evidence that Th2 cells play important roles during the inflammatory/maintenance phase of pulmonary fibrosis. Th2 cytokines IL-4, IL-5, and IL-13 have been causally linked to the development of fibrosis in several chronic inflammatory diseases. Overexpression of IL-4 or IL-13 in the lung of murine models showed a profibrotic role of both cytokines influencing the activation of myofibroblasts [10]. IL-5 can also promote fibrosis in the lung by recruiting eosinophils that produce TGF-β, platelet derived growth factor (PDGF), and IL-13.
It is well known the correlation between early ILD inflammatory phase and ground glass pattern on HRCT [28]. In this study, for the first time, we demonstrated a correlation between increased Th2 cytokine serum levels and the extent of ground glass pattern on HRCT. We may suppose that Th2 cytokine are involved in pulmonary inflammation in SSc patients and that have a pivotal role in damage repair mechanisms. Afterwards, Th2 cytokines are involved in induction and maintenance of fibrotic pathways (i.e. Smad) that lead to the activation of TGF-β, PDGF and IL-6 [28]. Increased expression of genes regulated by TGF-β has been confirmed in patients with progressive lung fibrosis. In our study, reticular and honeycombing pattern showed no correlation or showed a negative linear correlation with serum IL-4. Therefore, we may suppose that in the advanced stages of ILD profibrotic cytokines prevail, such as IL-6 and TGF-β, and Th2 cytokines are less secreted.
Ando et al. [29] demonstrated higher circulating eosinophils in SSc patients compared to patients with other systemic autoimmune diseases and they found an association between eosinophils count and severity of radiological ILD only in SSc patients. In our study we demonstrated a positive linear correlation between circulating eosinophil count and ground glass pattern measured by CALIPER software.
We also found a negative linear correlation between DLco and IL-4, IL-5, IL-31 and eosinophils. Moreover, in logistic regression analysis, IL-4 was the only variable associated to DLco ≤ 60% of the predicted. A previous study found a negative correlation between elevated IL-31 serum levels and DLco [25]. Previous studies demonstrated a negative linear correlation between eosinophils count in bronchoalveolar lavage fluid (BAL) and DLco [30, 31]. These findings support the role of Th2 inflammation in early stages of ILD characterized by a reduction of DLco with preserved FVC.
This study has some limitations: the monocentric design, the lack of data about Th2 cytokines and eosinophils in BAL and absence of fractional exhaled nitric oxide (FeNO) test.
Conclusions
We can conclude that serum level of Th2 cytokines were higher in SSc patients than HC. Th2 cytokines might have a key role in early phase of ILD in SSc patients and IL-4 was associated with DLco ≤ 60% of the predicted and with fibrotic involvement of ≥ 10% of lung parenchyma in SSc patients. Future large studies are needed to confirm these findings.
Abbreviations
- ACR/EULAR:
-
American College of Rheumatology/European League Against Rheumatism Collaborative Criteria
- BAL:
-
Bronchoalveolar lavage fluid
- CALIPER:
-
Computer-Aided Lung Informatics for Pathology Evaluation and Ratings
- DAI:
-
Ddisease activity inde
- dcSSc:
-
Diffuse cutaneous systemic sclerosis
- DLco:
-
Diffusion lung capacity for carbon monoxide
- DSS:
-
Disease severity scale
- FeNO:
-
Fractional exhaled nitric oxide
- FEV1:
-
Forced expiratory volume in the 1st second
- FVC:
-
Forced vital capacity
- HC:
-
Healthy controls
- HRCT:
-
High resolution computed tomography
- ILD:
-
Interstitial lung disease
- IQR:
-
Interquartile range
- lcSSc:
-
Limited cutaneous systemic sclerosis
- mRSS:
-
Modified Rodnan skin score
- NVC:
-
Nailfold videocapillaroscopy
- OR:
-
Odds ratio
- PAH:
-
Pulmonary arterial hypertension
- PDGF:
-
Platelet derived growth factor
- PFTs:
-
Pulmonary function tests
- SSc:
-
Systemic sclerosis
- TGF:
-
Transforming growth factor
References
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–99. https://doi.org/10.1016/S0140-6736(17)30933-9.
Hoffmann-Vold AM, Allanore Y, Alves M, et al. EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80:219–27. https://doi.org/10.1136/annrheumdis-2020-217455.
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15. https://doi.org/10.1136/ard.2009.114264.
Kase K, Watanabe S, Saeki S, et al. Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease. J Thorac Dis 2021;13:4146–55. https://doi.org/10.21037/jtd-20-2596.
Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55:1902026. https://doi.org/10.1183/13993003.02026-2019.
Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8:304–20. https://doi.org/10.1016/S2213-2600(19)30480-1.
Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc. 2016;13:2045–56. https://doi.org/10.1513/AnnalsATS.201606-426FR.
Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 58:1165–74. https://doi.org/10.1002/art.23406.
Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210. https://doi.org/10.1002/path.2277.
Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312:81–92. https://doi.org/10.1007/s00403-019-01972-3.
Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24:328–32.
Soman KV, Stafford SJ, Pazdrak K, et al. Activation of human peripheral blood eosinophils by cytokines in a comparative time-course proteomic/phosphoproteomic study. J Proteome Res. 2017;16:2663–79. https://doi.org/10.1021/acs.jproteome.6b00367.
Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15:271–82. https://doi.org/10.1038/nri3831.
Kloth C, Blum AC, Thaiss WM, et al. Differences in texture analysis parameters between active alveolitis and lung fibrosis in chest CT of patients with systemic sclerosis: a feasibility study. Acad Radiol. 2017;24:1596–603. https://doi.org/10.1016/j.acra.2017.07.002.
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47. https://doi.org/10.1002/art.38098.
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76:270–6. https://doi.org/10.1136/annrheumdis-2016-209768.
Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159–67.
Cutolo M, Matucci CM. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25:663–5.
Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardisation of spirometry Eur Respir J. 2005;26:319–38. https://doi.org/10.1183/09031936.05.00034805.
Distler O, Highland KB, Gahlemann M, et al; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380:2518–28. https://doi.org/10.1056/NEJMoa1903076.
Ferrazza AM, Gigante A, Gasperini ML, et al. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin Rheumatol. 2020;39:1537–42. https://doi.org/10.1007/s10067-020-04938-3.
Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol. 2009;21:617–22. https://doi.org/10.1097/BOR.0b013e32832fd69e.
O’Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012;51:1540–9. https://doi.org/10.1093/rheumatology/kes090.
Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12:5947. https://doi.org/10.1038/s41467-021-26099-w.
Gonçalves RSG, Pereira MC, Dantas AT, et al. IL-17 and related cytokines involved in systemic sclerosis: Perspectives. Autoimmunity. 2018;51:1–9. https://doi.org/10.1080/08916934.2017.1416467.
Gustafsson R, Fredens K, Nettelbladt O, Hällgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum. 1991;34:414–22. https://doi.org/10.1002/art.1780340406.
Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201:650–60. https://doi.org/10.1164/rccm.201903-0563CI.
Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S. Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity. Springerplus. 2016;5:1401. https://doi.org/10.1186/s40064-016-3106-4.
Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6. https://doi.org/10.1164/rccm.2106012.
Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1190;88:470–6. https://doi.org/10.1016/0002-9343(90)90425-d.
Funding
Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
Chiara Pellicano: Data curation, Formal analysis, Roles/Writing—original draft, Writing—review & editing; Lorenzo Vantaggio: Data curation, Roles/Writing—original draft; Amalia Colalillo: Data curation, Roles/Writing—original draft, Writing—review & editing; Krizia Pocino: Methodology, Roles/Writing—original draft; Valerio Basile: Methodology, Roles/Writing—original draft; Mariapaola Marino: Methodology, Roles/Writing—original draft; Umberto Basile: Methodology, Supervision, Roles/Writing—original draft, Writing—review & editing; Edoardo Rosato: Conceptualization, Supervision, Roles/Writing—original draft,Writing—review & editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sapienza University (IRB 0304).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Umberto Basile and Edoardo Rosato share senior authorship.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pellicano, C., Vantaggio, L., Colalillo, A. et al. Type 2 cytokines and scleroderma interstitial lung disease. Clin Exp Med 23, 3517–3525 (2023). https://doi.org/10.1007/s10238-023-01125-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-023-01125-x